U.S. Senate Aging Committee Chairman Sen. Rick Scott (R-Fla.) has co-sponsored a bipartisan bill cracking down on both foreign influence and control in U.S. pharmaceutical supply chains.
Alongside Minority Ranking Member Sen. Kirsten Gillibrand (D-N.Y.) and committee member Sen. Elizabeth Warren (D-Mass.), Sen. Scott introduced the Pharmaceutical Investment Oversight and Accountability Act.
The legislation aims “to bring much needed transparency” in the U.S.’s drug supply chain while also seeking to “hold the Chinese Communist Party (CCP) and other foreign adversaries accountable” for their increasing prominence in the industry.
“America has let the [CCP] and other foreign entities quietly buy their way into our drug supply for too long, and it needs to end,” Sen. Scott affirmed.
Bill Orders Agencies to 'Review' Foreign Control
The bill mandates the Federal Trade Commission (FTC) and the Committee on Foreign Investment in the U.S. (CFIUS) to review foreign control and influence in U.S. pharmaceutical production. The bill also orders both agencies to examine “sensitive biomedical technologies such as DNA sequencing and storage.”
“Everything from manufacturing and ingredient supplies to genomic sequencing technology is at stake,” Sen. Scott argued, claiming that the U.S. “has looked the other way for too long, and the truth is we don’t even know the full extent of how bad it is.”
“That’s why I’m proud to be working together to bring greater transparency on the full scope of foreign influence and control in” the U.S.’s pharmaceutical supply chain, the Florida Senator stated.
Sen. Scott's Prominent Role In Drug Supply Chain Reform
Both Sens. Scott and Gillibrand have been prominent advocates in pharmaceutical supply chain reform and transparency.
In Oct. 2025, both committee members released an investigative report revealing the U.S.’s “overreliance on foreign-made generic drugs and pharmaceutical ingredients.”
At the beginning of 2026, both Committee members also introduced the Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings (CLEAR LABELS) Act.
That bill also sought to add transparency measures by implementing “country of origin labeling requirements to the U.S.’s prescription drug supply chain.”
